World Pharma News Digest - 24.03.2014
4 views
Skip to first unread message
Ruslan David
Mar 24, 2014, 8:56:37 AM3/24/14
to worldph...@googlegroups.com
Novartis announces US FDA approval of Xolair® for chronic idiopathic urticaria
Novartis announced that the US Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), an unpredictable and debilitating skin disease that is known as chronic spontaneous urticaria (CSU) outside of the US. In the US, Xolair is indicated for CIU in adults and adolescents (12 years of age and above) who remain symptomatic despite H1-antihistamine treatment[5].
Read more...
http://www.worldpharmanews.com/novartis/2734-novartis-announces-us-fda-approval-of-xolairr-for-chronic-idiopathic-urticaria
New therapeutic target discovered for Alzheimer's disease
A team of scientists from the University of California, San Diego School of Medicine, the Medical University of South Carolina and San Diego-based American Life Science Pharmaceuticals, Inc., report that cathepsin B gene knockout or its reduction by an enzyme inhibitor blocks creation of key neurotoxic pGlu-Aβ peptides linked to Alzheimer's disease (AD). Moreover, the candidate inhibitor drug has been shown to be safe in humans.
Read more...
http://www.worldpharmanews.com/research/2733-new-therapeutic-target-discovered-for-alzheimers-disease
Multidisciplinary research team proposes new model for clinical trials
Experts across academia, industry and government propose a new method for health care providers to get the right treatments to the right patients at the right time. This new approach, A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials, published in Nature Clinical Pharmacology & Therapeutics, recommends a seamless transition from controlled experiments to real-world comparative effectiveness trials.
Read more...
http://www.worldpharmanews.com/research/2732-multidisciplinary-research-team-proposes-new-model-for-clinical-trials
Major breakthrough in developing new cancer drugs: Capturing leukemic stem cells
The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs.
Read more...
http://www.worldpharmanews.com/research/2731-major-breakthrough-in-developing-new-cancer-drugs-capturing-leukemic-stem-cells
Bayer to invest more than 500 million Euros for the manufacturing of hemophilia A products currently in development
With an investment of more than 500 million Euros at its sites in Wuppertal and Leverkusen, Germany, Bayer will establish additional capacities for the manufacturing of the recombinant factor VIII (rFVIII) hemophilia products that are currently in development. The investigational therapy options for hemophilia patients - a plasma protein-free rFVIII (BAY 81-8973) and a long-acting rFVIII (BAY 94-9027) - are both currently in Phase III clinical trials.
Read more...
http://www.worldpharmanews.com/bayer/2730-bayer-to-invest-more-than-500-million-euros-for-the-manufacturing-of-hemophilia-a-products-currently-in-development
Doctors 2.0 & You to address the "explosion of digital health tools" with new subjects, speakers, partners
5 - 6 June 2014, Paris, France.
Doctors 2.0 & You, partner of Stanford Medicine X and known for its 360° inclusive perspective on the patient, the physician, and digital tools, today announced 4th edition highlights. Remarking that "healthcare is now a recognized part of the explosion in social media, apps, quantified self and wearables," founder Denise Silber, confirms that "the June, 2014 program will provide an intensive look at the many moving parts of digital health and their results to date. How do patients and physicians benefit?"
Read more...
http://www.worldpharmanews.com/conferences/2729-doctors-20-a-you-to-address-the-qexplosion-of-digital-health-toolsq-with-new-subjects-speakers-partners
Five Prime Therapeutics and Bristol-Myers Squibb sign collaboration agreement
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) and Bristol-Myers Squibb Company (NYSE:BMY) have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's proprietary target discovery platform.
Read more...
http://www.worldpharmanews.com/bms/2728-five-prime-therapeutics-and-bristol-myers-squibb-sign-collaboration-agreement
PharmaNews.eu / Latest News
New approach makes cancer cells explode
http://www.pharmanews.eu/research-and-development/1421-new-approach-makes-cancer-cells-explode
Novartis reports data at EBCC-9 for secondary survival endpoint of Afinitor trial in HR+/HER2- advanced breast cancer
http://www.pharmanews.eu/novartis/1420-novartis-reports-data-at-ebcc-9-for-secondary-survival-endpoint-of-afinitor-trial-in-hrher2-advanced-breast-cancer
Doctors 2.0 & You to address the "explosion of digital health tools" with new subjects, speakers, partners
http://www.pharmanews.eu/conferences-and-events/1419-doctors-20-a-you-to-address-the-qexplosion-of-digital-health-toolsq-with-new-subjects-speakers-partners
Cancer therapy may be too targeted
http://www.pharmanews.eu/research-and-development/1418-cancer-therapy-may-be-too-targeted
Novo Nordisk invests 550 million Danish kroner in new purification pilot plant in Denmark
http://www.pharmanews.eu/novo-nordisk/1416-novo-nordisk-invests-550-million-danish-kroner-in-new-purification-pilot-plant-in-denmark
New IMI Project to Incorporate Real Life Data into Drug Development
http://www.pharmanews.eu/research-and-development/1417-new-imi-project-to-incorporate-real-life-data-into-drug-development
Strategies on the Internet to discredit generic drugs
http://www.pharmanews.eu/research-and-development/1415-strategies-on-the-internet-to-discredit-generic-drugs
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Novartis announced that the US Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), an unpredictable and debilitating skin disease that is known as chronic spontaneous urticaria (CSU) outside of the US. In the US, Xolair is indicated for CIU in adults and adolescents (12 years of age and above) who remain symptomatic despite H1-antihistamine treatment[5].
Read more...
http://www.worldpharmanews.com/novartis/2734-novartis-announces-us-fda-approval-of-xolairr-for-chronic-idiopathic-urticaria
New therapeutic target discovered for Alzheimer's disease
A team of scientists from the University of California, San Diego School of Medicine, the Medical University of South Carolina and San Diego-based American Life Science Pharmaceuticals, Inc., report that cathepsin B gene knockout or its reduction by an enzyme inhibitor blocks creation of key neurotoxic pGlu-Aβ peptides linked to Alzheimer's disease (AD). Moreover, the candidate inhibitor drug has been shown to be safe in humans.
Read more...
http://www.worldpharmanews.com/research/2733-new-therapeutic-target-discovered-for-alzheimers-disease
Multidisciplinary research team proposes new model for clinical trials
Experts across academia, industry and government propose a new method for health care providers to get the right treatments to the right patients at the right time. This new approach, A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials, published in Nature Clinical Pharmacology & Therapeutics, recommends a seamless transition from controlled experiments to real-world comparative effectiveness trials.
Read more...
http://www.worldpharmanews.com/research/2732-multidisciplinary-research-team-proposes-new-model-for-clinical-trials
Major breakthrough in developing new cancer drugs: Capturing leukemic stem cells
The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs.
Read more...
http://www.worldpharmanews.com/research/2731-major-breakthrough-in-developing-new-cancer-drugs-capturing-leukemic-stem-cells
Bayer to invest more than 500 million Euros for the manufacturing of hemophilia A products currently in development
With an investment of more than 500 million Euros at its sites in Wuppertal and Leverkusen, Germany, Bayer will establish additional capacities for the manufacturing of the recombinant factor VIII (rFVIII) hemophilia products that are currently in development. The investigational therapy options for hemophilia patients - a plasma protein-free rFVIII (BAY 81-8973) and a long-acting rFVIII (BAY 94-9027) - are both currently in Phase III clinical trials.
Read more...
http://www.worldpharmanews.com/bayer/2730-bayer-to-invest-more-than-500-million-euros-for-the-manufacturing-of-hemophilia-a-products-currently-in-development
Doctors 2.0 & You to address the "explosion of digital health tools" with new subjects, speakers, partners
5 - 6 June 2014, Paris, France.
Doctors 2.0 & You, partner of Stanford Medicine X and known for its 360° inclusive perspective on the patient, the physician, and digital tools, today announced 4th edition highlights. Remarking that "healthcare is now a recognized part of the explosion in social media, apps, quantified self and wearables," founder Denise Silber, confirms that "the June, 2014 program will provide an intensive look at the many moving parts of digital health and their results to date. How do patients and physicians benefit?"
Read more...
http://www.worldpharmanews.com/conferences/2729-doctors-20-a-you-to-address-the-qexplosion-of-digital-health-toolsq-with-new-subjects-speakers-partners
Five Prime Therapeutics and Bristol-Myers Squibb sign collaboration agreement
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) and Bristol-Myers Squibb Company (NYSE:BMY) have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's proprietary target discovery platform.
Read more...
http://www.worldpharmanews.com/bms/2728-five-prime-therapeutics-and-bristol-myers-squibb-sign-collaboration-agreement
PharmaNews.eu / Latest News
New approach makes cancer cells explode
http://www.pharmanews.eu/research-and-development/1421-new-approach-makes-cancer-cells-explode
Novartis reports data at EBCC-9 for secondary survival endpoint of Afinitor trial in HR+/HER2- advanced breast cancer
http://www.pharmanews.eu/novartis/1420-novartis-reports-data-at-ebcc-9-for-secondary-survival-endpoint-of-afinitor-trial-in-hrher2-advanced-breast-cancer
Doctors 2.0 & You to address the "explosion of digital health tools" with new subjects, speakers, partners
http://www.pharmanews.eu/conferences-and-events/1419-doctors-20-a-you-to-address-the-qexplosion-of-digital-health-toolsq-with-new-subjects-speakers-partners
Cancer therapy may be too targeted
http://www.pharmanews.eu/research-and-development/1418-cancer-therapy-may-be-too-targeted
Novo Nordisk invests 550 million Danish kroner in new purification pilot plant in Denmark
http://www.pharmanews.eu/novo-nordisk/1416-novo-nordisk-invests-550-million-danish-kroner-in-new-purification-pilot-plant-in-denmark
New IMI Project to Incorporate Real Life Data into Drug Development
http://www.pharmanews.eu/research-and-development/1417-new-imi-project-to-incorporate-real-life-data-into-drug-development
Strategies on the Internet to discredit generic drugs
http://www.pharmanews.eu/research-and-development/1415-strategies-on-the-internet-to-discredit-generic-drugs
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages